-
公开(公告)号：US20240294608A1
公开(公告)日：2024-09-05
申请号：US18421886
申请日：2024-01-24
发明人： James JOWETT , David James BALLANCE
IPC分类号： C07K14/78 , A61K9/00 , A61K38/00 , A61K47/02 , A61K47/22 , C07K14/00 , C07K14/50 , C07K14/575 , C07K14/605
CPC分类号： C07K14/78 , A61K9/0019 , A61K9/0024 , A61K47/02 , A61K47/22 , C07K14/00 , C07K14/50 , C07K14/575 , C07K14/605 , A61K38/00 , C07K2319/31
摘要： The present disclosure provides pharmaceutical formulations for sustained release, and methods for delivering a treat-ment regimen with a combination of sustained release and long half-life formulations. The disclosure provides improved pharmacoki-netics for peptide and small molecule drugs.
-
公开(公告)号：US20240294501A1
公开(公告)日：2024-09-05
申请号：US18581700
申请日：2024-02-20
IPC分类号： C07D401/14 , C07D401/04 , C07K14/495 , C07K14/50 , C12N5/071
CPC分类号： C07D401/14 , C07D401/04 , C07K14/495 , C07K14/50 , C12N5/0676 , C12N2501/117 , C12N2501/155 , C12N2501/16 , C12N2501/385 , C12N2501/41
摘要： Disclosed herein are compositions and methods useful for manufacturing SC-β cell, and isolated populations of SC-β cells for use in various applications, such as cell therapy.
-
3.发明公开公开(公告)号：US20240293508A1
公开(公告)日：2024-09-05
申请号：US18609420
申请日：2024-03-19
申请人： Novartis AG
CPC分类号： A61K38/1825 , C07K14/50 , C07K2319/30
摘要： The invention relates to the identification of new therapeutic methods for the FGF21 polypeptide or protein, or mutants, variants, and fusions thereof, for instance, in treating metabolic diseases associated defects in insulin signaling (e.g. insulin receptor mutation disorders (INSR disorders) and/or autoimmune insulin receptor disorders (Type B insulin Resistance)), defects in insulin production such as type 1 diabetes mellitus, mixed dyslipidemia, nonalcoholic fatty liver disease (NAFLD), and other metabolic disorders, and various lipodystrophies such as HIV-HAART induced partial-lipodystrophy, and in reducing the mortality and morbidity of critically ill patients.
-
公开(公告)号：US20240261371A1
公开(公告)日：2024-08-08
申请号：US17999903
申请日：2021-05-27
发明人： Wei XIAO , Deshan LI , Dan YU , Zhihang LIU , Zhenzhong WANG , Chengkai YIN , Xu SUN
CPC分类号： A61K38/1825 , A61P3/10 , C07K7/06 , C07K14/50 , C07K2319/31
摘要： A recombinant human fibroblast growth factor 21 (rhFGF21) fusion protein, a polynucleotide encoding the rhFGF21 fusion protein, a recombinant expression vector, a recombinant cell, a pharmaceutical composition and a kit containing the rhFGF21 fusion protein, a use of the rhFGF21 fusion protein, and a method for producing the rhFGF21 fusion protein. Efficient and soluble expression is achieved using a genetic engineering method to obtain a rhFGF21-(VPGXG)n fusion protein, wherein by means of fusion of rhFGF21 and an elastin-like protein (VPGXG)n having an appropriate cycle number n, the resulting fusion protein has better biological activity than wild-type rhFGF21. Moreover, experimental results indicate that the rhFGF21-(VPGXG)n fusion protein has high expression efficiency, and can effectively reduce the blood sugar level in the body of a diabetic animal. In addition, compared with wild-type hFGF21, the fusion protein also has the advantage of a long efficacy duration in reducing the blood sugar level.
-
公开(公告)号：US20240247038A1
公开(公告)日：2024-07-25
申请号：US18431592
申请日：2024-02-02
发明人： Jeffrey L. SPEES , Benjamin LIEBMAN
IPC分类号： C07K14/50 , A61K38/00 , A61P9/10 , C07K14/705
CPC分类号： C07K14/50 , A61P9/10 , C07K14/70596 , A61K38/00 , C07K2319/30
摘要： The invention features isolated protein complexes and compositions and methods for use thereof. In embodiments, the isolated protein complexes are used for treating conditions associated with reperfusion injury, hypofusion, and/or low/no-reflow. The isolated protein complexes comprise a fusion protein complexed with basic fibroblast growth factor (FGF2), hepatocyte growth factor (HGF), or vascular endothelial growth factor (VEGF). The fusion protein contains an immunoglobulin G (IgG) Fc domain fused to a polypeptide (e.g., Jagged1, a growth factor, or a cytokine).
-
公开(公告)号：US20240229058A9
公开(公告)日：2024-07-11
申请号：US18344933
申请日：2023-06-30
申请人： TIAMAT SCIENCES
CPC分类号： C12N15/8257 , A01H6/823 , C07K1/22 , C07K14/485 , C07K14/503 , C07K14/65 , C12N15/8205
摘要： The present disclosure provides composition, systems, devices and methods for plant-based production of non-plant proteins through the use of heterologous genes for the expression of said non-plant proteins. Non-plant proteins can include, but are not limited to, mammalian proteins, cytokines, or growth factors.
-
公开(公告)号：US20240228566A1
公开(公告)日：2024-07-11
申请号：US18431661
申请日：2024-02-02
发明人： Jeffrey L. SPEES , Benjamin LIEBMAN
IPC分类号： C07K14/475 , A61P9/10 , C07K14/50 , C07K16/22 , A61K38/00
CPC分类号： C07K14/4753 , A61P9/10 , C07K14/503 , C07K16/22 , A61K38/00
摘要： The invention features methods and compositions for treating a reperfusion injury, hypofusion, ischemic injury, and/or low/no-reflow. In embodiments, the compositions contain complexes containing a basic fibroblast growth factor (FGF2) and an immunoglobulin G (IgG) polypeptide, or fragments thereof. In embodiments, the complexes further contain a hepatocyte growth factor (HGF) polypeptide, a vascular endothelial growth factor (VEGF) polypeptide, or fragments thereof.
-
公开(公告)号：US12030921B2
公开(公告)日：2024-07-09
申请号：US17819766
申请日：2022-08-15
申请人： Jiangnan University
发明人： Shenglong Zhu , Yongquan Chen , Zhen Wang
CPC分类号： C07K14/50 , A61K9/0019 , A61K9/0053 , A61K38/1825 , A61P1/16 , A61P3/00 , A61P35/00
摘要： The disclosure discloses an anti-metabolic disorder FGF analog and an application thereof, and belongs to the technical field of medicines. According to the disclosure, modification is performed based on an FGF19 mutant NGM282 to obtain a FGF19 analog, and the FGF19 analog is used in treating liver impairment, metabolic disorders, obesity, overweight, metabolic syndrome, diabetes and dyslipidemia and has no side effects of elevated cholesterol and dietary decline in a therapeutic process.
-
公开(公告)号：US20240209046A1
公开(公告)日：2024-06-27
申请号：US18453221
申请日：2023-08-21
发明人： Sung Hyun Kim , Jin Ho Bang , Mi Hyun Choi , Seho Park
IPC分类号： C07K14/47 , C07K1/30 , C07K14/475 , C07K14/485 , C07K14/50 , C07K14/51 , C07K14/605 , C07K14/745 , C07K14/78 , C12N9/08 , C12N9/50 , C12N15/70 , C12P21/02
CPC分类号： C07K14/4728 , C07K1/303 , C07K14/475 , C07K14/485 , C07K14/50 , C07K14/51 , C07K14/605 , C07K14/745 , C07K14/78 , C12N9/0065 , C12N9/506 , C12N15/70 , C12P21/02 , C12Y111/01007 , C12Y304/22044 , C07K2319/20
摘要： The present disclosure relates to a method for expressing, water-solubilizing, and purifying protein by using a calsequestrin-tag (CSQ-tag). Also provided are: a recombinant expression vector containing a CSQ-tag and a target protein; a host cell transformed using the recombinant expression vector; and a method for expressing and purifying a target protein by using a CSQ tag.
-
公开(公告)号：US20240182858A1
公开(公告)日：2024-06-06
申请号：US18282450
申请日：2022-03-16
发明人： Kenichiro SHIMATANI , Hiromu SATO , Masao SASAI , Yoshiki SAWA , Atsuhiro SAITO , Shigeru MIYAGAWA
CPC分类号： C12N5/0661 , A61K35/44 , A61P7/00 , C07K14/503 , C12N5/10
摘要： An object of the present invention is to provide a cell therapy that is expected to be useful as an angiogenic therapy for a peripheral vascular disease such as critical lower limb ischemia. Specifically, the object is to provide a pericyte having high angiogenic potential and a method for producing the same. A pericyte introduced a bFGF gene and a method for producing the same are provided.
-
-
-
-
-
-
-
-
-
搜索结果
986 条记录 (耗时 0.037 秒)
